• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Chronic Disease

Anti-HLA antibodies predict worse kidney-allograft survival

bys25qthea
September 25, 2013
in Chronic Disease, Nephrology, Surgery
Reading Time: 3 mins read
Urinary mRNA profiling accurately diagnoses rejection in kidney allografts
Share on FacebookShare on TwitterShare on LinkedIn

Image: PD

1. C1q-binding donor-specific anti-HLA antibodies predicted worse graft survival in kidney transplant patients. 

2. Inclusion of C1q-binding donor-specific anti-HLA antibodies improved risk stratification. 

Evidence Rating Level: 2 (Good)

Study Rundown: This study demonstrated that donor-specific anti-HLA antibodies were heterogeneous and that their ability to bind complement significantly impacted kidney-allograft survival. This is not surprising, as antibody-mediated activation of the complement system represents one of the main mechanisms for allograft injury, together with T-cell mediated cytotoxicity. The study concluded that including the presence of complement-binding antibodies improved discrimination capacity and continuous net reclassification in the reference model. These results highlight the need for therapies targeting complement to improve survival in patients with complement-binding anti-HLA antibodies. The study has a strong design with over 1000 subjects and is well-controlled for subgroup differences, especially populations across the two transplant centers in Paris.

Click to read the study, published today in NEJM

RELATED REPORTS

Yartemlea (narsoplimab-wuug) improves platelets hemolysis organ function hematopoietic stem cell transplant–associated thrombotic microangiopathy transplant patients

Recognition of kidney allograft microvascular inflammation refines risk stratification for allograft outcomes

Click to read an accompanying editorial in NEJM

Relevant Reading: Rejection of the Kidney Allograft

In-Depth [prospective cohort study]: This study sought to determine whether C1q-binding donor-specific anti-HLA antibodies had any predictive power in kidney-allograft survival. Patients with C1q-binding donor-specific anti-HLA antibodies had a lower eGFR at 1 year (42±22 ml/min) than did patients with non-C1q-binding donor-specific anti-HLA antibodies (51±20 ml/min) and patients without such antibodies (54±19 ml/min). C1q-binding donor-specific anti-HLA antibodies were also associated with the worst 5-year graft survival rate (54%), as compared to patients with non-C1q-binding donor-specific anti-HLA antibodies and those without such antibodies (93% and 94%, respectively; P<0.001 for both comparisons).

Multivariate regression analysis identified 4 independent graft-loss predictors: low eGFR at 1 year (hazard ratio, 12.49), interstitial fibrosis and tubular atrophy (hazard ratio, 2.22), glomerular and peritubular inflammation and transplant glomerulopathy (hazard ratio, 2.26), and the presence of complement-binding donor-specific anti-HLA antibodies (hazard ratio, 4.78).

Finally, including complement-binding donor-specific anti-HLA antibodies in the reference model improved risk stratification, as shown by a continuous net reclassification improvement of 0.75 (95% CI, 0.54 to 0.97).

By Xiaozhou Liu and Adrienne Cheung

More from this author: Nivolumab plus ipilimumab shows promise for metastatic melanoma, Prophylactic platelet transfusions prevent bleeding in hematologic cancers, Azithromycin is not associated with increased cardiovascular death in low-risk groups, Health education module reduces parasitic infections, New chemotherapy precludes the need for radiotherapy in primary mediastinal B-cell lymphoma.

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: HLAkidney transplanttransplant
Previous Post

Repeat bone mineral density testing may not improve prediction of fracture outcomes

Next Post

Half of C. difficile cases genetically distinct from previous cases

RelatedReports

Small-vessel clotting disease collage: a calm man in a zip jacket beside an opened blood vessel with red cells and platelets
All Specialties

Yartemlea (narsoplimab-wuug) improves platelets hemolysis organ function hematopoietic stem cell transplant–associated thrombotic microangiopathy transplant patients

January 15, 2026
Tenofovir disoprovil fumarate HIV prophylaxis linked with minimal kidney impact
Chronic Disease

Recognition of kidney allograft microvascular inflammation refines risk stratification for allograft outcomes

March 12, 2025
Kidney transplant collage: a young man in a crewneck sweater beside an engraved kidney ringed by small viruses and a fern
Oncology

High incidence of post-transplant lymphoproliferative disorder in Epstein-Barr virus-seronegative kidney recipients

January 27, 2025
Infectious Disease

Kidneys from donors with HIV have good safety outcomes in persons with HIV

November 22, 2024
Next Post
Half of C. difficile cases genetically distinct from previous cases

Half of C. difficile cases genetically distinct from previous cases

Effective CMV infection prophylaxis for hematopoietic-cell transplantation

Effective CMV infection prophylaxis for hematopoietic-cell transplantation

Buccal administration of dextrose gel effective for neonatal hypoglycemia

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Inhaled corticosteroids do not improve outcomes in sickle cell disease patients without asthma
  • Interim global phase 2 AZUR-1 results show durable responses with dostarlimab monotherapy in untreated MSI-H/dMMR stage II/III locally advanced rectal cancer
  • AI health chatbot shows no benefit for perinatal anxiety or depression
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.